Remimazolam

Remimazolam

Trade names	Byfavo
Clinical data
Drug class	Sedative hypnotic
Uses	Sedation
Routes of administration	Intravenous
Dosage
Remimazolam Adult dosing 2.5-5 mg IV q2m 2.5-5 mL of 1 mg/mL Weight kglbg Height cmminft Age yrmowk SexFM Indication  Indication: Monitored anesthesia care Route  Route: Intravenous Preparation  Preparation: 1 mg/mL
Pharmacodynamics
Mechanism of action	GABA agonism
Pharmacokinetics
Physical and chemical data
Article quality
Editor rating	Unrated
User likes	0

Remimazolam is an ultra-short acting benzodiazepine. It possesses the same sedative effects as other benzodiazepines but is metabolized by plasma esterase, allowing it to be titrated for procedural sedation cases. Its use for broader scope (general anesthesia) is being investigated.

Uses

Initial trials have proven to be successful for bronchoscopy, upper endoscopy, and colonoscopy. It is FDA approved in the US for all procedural sedation. Its use is actively being studied for other indications as well including general anesthesia induction/maintenance and long-term sedation.

Contraindications

Absolute contraindications

• Dextran 40 allergy
• Severe hepatic dysfunction